Abstract The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes
genotype-based drug guidelines to help clinicians understand how available genetic test …

The cytochrome P450 2D6 (CYP2D6) enzyme contributes to the metabolism and/or
bioactivation of approximately 25% of clinically used drugs. The CYP2D6 gene locus is …

Since September 2010, more than 10,000 patients have undergone preemptive, panel‐
based pharmacogenomic testing through the Vanderbilt Pharmacogenomic Resource for …

Background Active clinical decision support (CDS) delivered through an electronic health
record (EHR) facilitates gene-based drug prescribing and other applications of genomics to …

Clinical genetic testing began over 30 years ago with the availability of mutation detection
for sickle cell disease diagnosis. Since then, the field has dramatically transformed to …

Abstract Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of 25% of clinically
used drugs. Genetic polymorphisms cause substantial variation in CYP2D6 activity and …

Antipsychotic medications are the gold-standard treatment for schizophrenia, and are often
prescribed for other mental conditions. However, the efficacy and side-effect profiles of these …

Obsessive–compulsive disorder (OCD) is a common heterogeneous psychiatric disorder
manifesting with obsessions and compulsions. Obsessions are intrusive, recurrent, and …

Advancements in pharmacogenomics have introduced an increasing number of
opportunities to bring personalized medicine into clinical practice. Understanding how and …

The potential for personalized sequencing to individually optimize medical treatment in
diseases such as cancer and for pharmacogenomic application is just beginning to be …